https://www.marketscreener.com/quote/stock/INCANNEX-HEALTHCARE-INC-133985168/news/Incannex-Commences-Dosing-in-Phase-2-Clinical-Trial-Assessing-IHL-675A-in-Patients-with-Rheumatoid-A-45807381/?utm_source=telegram&utm_medium=social&utm_campaign=share